Ownership and insider activity for Immuneering Corporation (IMRX): insider transactions, US Senate and House trading disclosures and shares outstanding. Track how corporate insiders and politicians are trading the stock.
Immuneering Corporation is a biopharmaceutical company dedicated to developing novel therapeutic candidates in the fields of oncology (cancer) and neuroscience. Leading its clinical development efforts are two key drug candidates: IMM-1-104, a dual-MEK inhibitor intended for the treatment of various cancers, including pancreatic, melanoma, colorectal, and non-small cell lung cancer, specifically those driven by RAS and/or RAF gene mutations.
Price
| Price | $4.45 |
| Market Cap | $162M |
| Exchange | NASDAQ |
| Country | US |
Recent Insider Transactions
| Date | Insider | Type | Shares | Value |
|---|---|---|---|---|
| 2026-07-16 | Gengos Andrew | A-Award | 650,000 | $3.1M |
| 2026-07-16 | Gengos Andrew | |||
| 2026-06-23 | Zeskind Benjamin J. | P-Purchase | 2,400 | $11K |
| 2026-06-15 | Hall Brett Matthew | P-Purchase | 6,035 | $25K |
| 2026-06-11 | Schall Thomas J. | A-Award | 33,350 | $137K |
| 2026-06-11 | HAUSMAN DIANA | A-Award | 33,350 | $137K |
| 2026-06-11 | CARPENTER ROBERT J | A-Award | 33,350 | $137K |
| 2026-06-11 | KEATING LAURIE | A-Award | 33,350 | $137K |
| 2026-06-11 | Feinberg Peter | A-Award | 33,350 | $137K |
| 2026-03-13 | Neufeld Leah R | A-Award | 3,628 | $16K |
Balance Sheet (10y)
| Year | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $13.8M | $37.1M | $74.9M | $72.6M | $59.4M | $36.1M | $128.6M |
| Short-term Investments | 0 | 0 | $74.3M | $32.9M | $26.3M | 0 | $44.2M |
| Receivables | $209940 | $500110 | $246040 | $12417 | 0 | 0 | 0 |
| Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Current Assets | $14.1M | $37.7M | $152.3M | $108.7M | $89.1M | $39.6M | $176.2M |
| Property, Plant & Equipment | $35276 | $677466 | $6.1M | $5.8M | $5.4M | $4.8M | $4.3M |
| Goodwill | 0 | 0 | $6.7M | $6.7M | $6.7M | $6.7M | $6.7M |
| Intangible Assets | 0 | 0 | $439000 | $408947 | $379680 | $350413 | $321147 |
| Total Assets | $14.1M | $38.4M | $166.7M | $122.4M | $102.6M | $52.7M | $232.0M |
| Accounts Payable | $294948 | $1.5M | $1.4M | $3.2M | $2.1M | $2.0M | $1.5M |
| Short-term Debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Current Liabilities | $505296 | $2.3M | $5.6M | $8.1M | $7.8M | $7.5M | $10.1M |
| Long-term Debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Liabilities | $20.6M | $60.9M | $10.7M | $12.5M | $12.0M | $11.3M | $13.5M |
| Retained Earnings | -$8.7M | -$25.7M | -$59.3M | -$109.8M | -$163.3M | -$224.3M | -$280.3M |
| Total Equity | -$6.5M | -$22.5M | $156.0M | $109.9M | $90.6M | $41.4M | $218.5M |
| Total Debt | 0 | $621089 | $5.4M | $4.8M | $4.5M | $4.2M | $3.8M |
| Net Debt | -$13.8M | -$36.5M | -$143.8M | -$100.7M | -$81.2M | -$32.0M | -$169.0M |
| Working Capital | $13.6M | $35.5M | $146.7M | $100.7M | $81.2M | $32.1M | $166.2M |
Financial Health
| Debt / Equity | 0.02 |
| Current Ratio | 19.47 |
| Piotroski F-Score | 3 |
| Altman Z-Score | 11.19 |
Profitability
| Return on Equity | -27.15% |
| Return on Invested Capital | -32.65% |
| Return on Assets | -28.35% |
| Gross Margin | 0.00% |
| Operating Margin | 0.00% |
| Net Margin | 0.00% |
Related companies: ARCT · ASMB · ENTA · FHTX · HUMA · NAUT · PYXS
Explore sector: Healthcare · Biotechnology
More sections of IMRX: Overview · Financials · Valuation · Statistics · Estimates · Technical · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks